Altered First-Pass Effects in a Liver Transplant Recipient Explained Intraindividual Variation in Calcineurin Inhibitor Concentrations: A Case Report

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1789-1791

  Malireddy, S R ^a   Pinto, A G ^a   Chalasani, N P ^a   Gorski, J C ^a   Hall, S D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; MIDAZOLAM; NITROGEN 15; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FIRST PASS EFFECT; GRAFT RECIPIENT; HUMAN; INTESTINE BIOPSY; LIVER TRANSPLANTATION; MALE; NAUSEA; PRIORITY JOURNAL; TREMOR;

ADULT; BIOPSY; CALCINEURIN; CHOLANGITIS, SCLEROSING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; LIVER TRANSPLANTATION; MALE; MASS SPECTROMETRY; MIDAZOLAM; TACROLIMUS;

EID: 45449096689     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.02.073     Document Type: Article

References (13)

1. Hebert M.F. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27 (1997) 201
2. Benet L.Z., Izumi T., Zhang Y., et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62 (1999) 25
3. Shen D.D., Kunze K.L., and Thummel K.E. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27 (1997) 99
4. Kronbach T., Fischer V., and Meyer U.A. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43 (1988) 630
5. Lindholm A., Henricsson S., Lind M., et al. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 34 (1988) 461
6. Thummel K.E., Shen D.D., Podoll T.D., et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271 (1994) 549
7. Thummel K.E., Shen D.D., Podoll T.D., et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271 (1994) 557
8. Villeneuve J.P., L'Ecuyer L., De Maeght S., et al. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. Clin Pharmacol Ther 67 (2000) 242
9. Pinto A.G., Horlander J., Chalasani N., et al. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol 59 (2005) 440
10. Lowry O.H., Rosebrough N.J., Farr A.L., et al. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265
11. Gorski J.C., Vannaprasaht S., Hamman M.A., et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74 (2003) 275
12. Lemahieu W.P., Maes B.D., and Vanrenterghem Y. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. Transplant Proc 37 (2005) 2051
13. Pinto A.G., Wang Y.H., Chalasani N., et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 77 (2005) 178